Fig. 6.
R1479, 2′F-4′N3-C, and 2′diF-4′N3-C inhibit Ebola virus (EBOV) variants but not Rift Valley fever virus (RVFV). Representative dose-response curves for R1479 (green circles), 2′F-4′N3-C (blue triangles), and 2′diF-4′N3-C (red squares) against recombinant reporter (a) EBOV-Mayinga variant, (b) EBOV-Makona variant, and (c) RVFV expressing green fluorescent proteins. (d) Representative dose-response curves of the same compounds against wild-type EBOV (2014 Makona variant) using a focus forming unit (FFU) assay. FFU assays against EBOV were repeated once for R1479, twice for 2′diF-4′N3-C, and was performed once for 2′F-4′N3-C. (e) Representative composite micrographs of FFU assays in individual wells of a 96-well plate of R1479-treated, EBOV-infected, formalin-inactivated NCI-H358 cells stained with anti-EBOV polyclonal sera and Dylight-488 conjugated secondary antibody. Concentrations of R1479 (in μM) are indicated above each pictured well.